Fig. 6: Commercial lateral flow approaches for detecting glycosylated fibronectin.
From: Biomarkers and point of care screening approaches for the management of preeclampsia
Lumella is a commercial POC test developed by Diabetomics Inc for targeting glycosylated fibronectin (GlyFn)127,143. The top images show the actual device (left) and machine that reads the cartridge (right). The lower diagram explains how the device works: Diluted fingerstick whole blood is applied to lateral flow testing strips containing gold nanoparticles coated with an anti-GlyFn monoclonal antibody. Capture of colloidal gold-fibronectin complexes at the test line by another anti-GlyFn monoclonal antibody results in the formation of a reddish-purple line. Based on the depth of color at the test line the reader is able to interpret whether the GlyFn levels are in the normal (50–350 µg/mL), positive (351–600 µg/mL, increased risk of preeclampsia) or high positive ( > 600 µg/mL, increased risk of severe preeclampsia) ranges. Created with BioRender.com
